RCT of Glecaprevir/Pibrentasvir for the Treatment of PTSD
Status:
Not yet recruiting
Trial end date:
2026-09-30
Target enrollment:
Participant gender:
Summary
The goal of this randomized control trial is to measure the effect of an antiviral
medication, Glecaprevir/Pibrentasvir (GLE/PIB), on symptoms of post-traumatic stress
disorder. The main questions this study will answer are: Is GLE/PIB effective in improving
PTSD symptoms? What is the tolerability of GLE/PIB in those experiencing PTSD? Participants
will be randomized into one of two study arms, active medication, or inactive medication
(placebo), take active or placebo medication once a day for 8-weeks, provide blood samples at
two time points, and complete surveys at eight time points during the eight-month study
period.
Phase:
Phase 2
Details
Lead Sponsor:
White River Junction Veterans Affairs Medical Center